Capture SBIR Phase II Success Premium via Predictive Biotech Intelligence Database
- Organization
- National Science Foundation SBIR program structure that funds technical feasibility but provides zero strategic guidance on follow-on funding success
- Sector
- SBIR Phase I-funded biotech companies facing 6-month deadline to secure Phase II survival funding
- Location
- Carlsbad, CA
Source reference
Executive summary
Current state
NSF awarded $305,000 SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a PKU microbiome therapeutic platform, creating a 6-month window where the company must prove technical feasibility but lacks strategic guidance, vendor intelligence, and IP protection for the critical Phase II transition required for survival.
Market catalyst
ENDURE has $305k with 6-month expiration but lacks the data-driven intelligence to maximize their Phase II success probability. The SBIR system provides capital but no strategic guidance on which vendor choices, investor targets, or competitive positioning will secure the critical $2M+ Phase II follow-on funding required for survival.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.